SpringerLink
Log in

Prescription of rh-APC differs substantially among western European countries

  • Correspondence
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709.

    Article  PubMed  CAS  Google Scholar 

  2. Bernard GR, Margolis BD, Shanies HM, Ely EW, Wheeler AP, Levy H, Wong K, Wright TJ (2004) Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 125:2206–2216

    Article  PubMed  CAS  Google Scholar 

  3. Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33:2266–2277

    Article  PubMed  CAS  Google Scholar 

  4. Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C (2002) An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 347:993–1000

    Article  PubMed  Google Scholar 

  5. Davies A, Ridley S, Hutton J, Chinn C, Barber B, Angus DC (2005) Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Anaesthesia 60:155–162

    Article  PubMed  CAS  Google Scholar 

  6. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32:858–873

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Intensive Care Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

    Marcus J. Schultz

  2. Interdepartmental Division of Critical Care, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada

    Marcus J. Schultz

  3. Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

    Marcel Levi

Authors
  1. Marcus J. Schultz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcel Levi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcus J. Schultz.

Electronic Supplementary Material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schultz, M.J., Levi, M. Prescription of rh-APC differs substantially among western European countries. Intensive Care Med 32, 630–631 (2006). https://doi.org/10.1007/s00134-006-0075-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-006-0075-z

Keywords

Search

Navigation